Roche’s CT-388 shows promising results in Phase I trial for obesity and Type 2 diabetes treatment

Roche has announced positive outcomes from the Phase I clinical trial of CT-388, a novel dual GLP-1/GIP receptor agonist, which is being developed as a ... Read More